InvestorNews

The new Business Plan for the 2018-2022 period starts with a convincing performance already in its first year; our forecast for 2018 EBITDA is 1,020 m€, a growth of 35 €m compared to 2017. Over the last two years, Hera has therefore achieved an EBITDA increase exceeding by 16 m€ that included in the rolling Plan to 2021. Actually, we fully delivered the target of cumulated growth of 210 m€ that we had announced in 2013 for the following five-year period.

Despite the remarkable recovery achieved from 10 December 2018 onwards, Hera stock continues to trade at a discount compared to the consensus target price of broker coverage, presently at 3.28 euro. Most analyst ratings indicate buying suggestions, with only one neutral rating and no selling recommendation.